IL278041A - Bezumab formulations with a buffer for use in the treatment of diseases - Google Patents
Bezumab formulations with a buffer for use in the treatment of diseasesInfo
- Publication number
- IL278041A IL278041A IL278041A IL27804120A IL278041A IL 278041 A IL278041 A IL 278041A IL 278041 A IL278041 A IL 278041A IL 27804120 A IL27804120 A IL 27804120A IL 278041 A IL278041 A IL 278041A
- Authority
- IL
- Israel
- Prior art keywords
- bevacizumab
- treating diseases
- buffered formulations
- buffered
- formulations
- Prior art date
Links
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
- A61K39/39591—Stabilisation, fragmentation
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
- C07K16/22—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against growth factors ; against growth regulators
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/02—Inorganic compounds
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
- A61K47/08—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing oxygen, e.g. ethers, acetals, ketones, quinones, aldehydes, peroxides
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
- A61K47/08—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing oxygen, e.g. ethers, acetals, ketones, quinones, aldehydes, peroxides
- A61K47/12—Carboxylic acids; Salts or anhydrides thereof
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
- A61K47/26—Carbohydrates, e.g. sugar alcohols, amino sugars, nucleic acids, mono-, di- or oligo-saccharides; Derivatives thereof, e.g. polysorbates, sorbitan fatty acid esters or glycyrrhizin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/30—Macromolecular organic or inorganic compounds, e.g. inorganic polyphosphates
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/0012—Galenical forms characterised by the site of application
- A61K9/0019—Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/0012—Galenical forms characterised by the site of application
- A61K9/0048—Eye, e.g. artificial tears
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P27/00—Drugs for disorders of the senses
- A61P27/02—Ophthalmic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Medicinal Chemistry (AREA)
- General Health & Medical Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- Pharmacology & Pharmacy (AREA)
- Epidemiology (AREA)
- Organic Chemistry (AREA)
- Engineering & Computer Science (AREA)
- Immunology (AREA)
- Biochemistry (AREA)
- Molecular Biology (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Oil, Petroleum & Natural Gas (AREA)
- Genetics & Genomics (AREA)
- Biophysics (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Ophthalmology & Optometry (AREA)
- Microbiology (AREA)
- Mycology (AREA)
- Inorganic Chemistry (AREA)
- Dermatology (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
- Medicinal Preparation (AREA)
- Peptides Or Proteins (AREA)
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201862658772P | 2018-04-17 | 2018-04-17 | |
| US201862776686P | 2018-12-07 | 2018-12-07 | |
| PCT/US2019/027790 WO2019204380A1 (en) | 2018-04-17 | 2019-04-17 | Buffered formulations of bevacizumab for use of treating diseases |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| IL278041A true IL278041A (en) | 2020-11-30 |
Family
ID=66429576
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| IL278041A IL278041A (en) | 2018-04-17 | 2020-10-14 | Bezumab formulations with a buffer for use in the treatment of diseases |
Country Status (12)
| Country | Link |
|---|---|
| US (1) | US20210230261A1 (enExample) |
| EP (1) | EP3781199A1 (enExample) |
| JP (1) | JP2021522180A (enExample) |
| KR (1) | KR20210011923A (enExample) |
| CN (1) | CN112543645A (enExample) |
| AU (1) | AU2019256289A1 (enExample) |
| BR (1) | BR112020021255A2 (enExample) |
| CA (1) | CA3097123A1 (enExample) |
| IL (1) | IL278041A (enExample) |
| MX (1) | MX2020010968A (enExample) |
| SG (1) | SG11202010178XA (enExample) |
| WO (1) | WO2019204380A1 (enExample) |
Families Citing this family (11)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| WO2015200905A2 (en) | 2014-06-28 | 2015-12-30 | Oligasis, Llc | Dual pdgf/vegf antagonists |
| IL290457B2 (en) | 2015-12-30 | 2025-02-01 | Kodiak Sciences Inc | Antibodies and their conjugates |
| CA3092588A1 (en) | 2018-03-02 | 2019-09-06 | Kodiak Sciences Inc. | Il-6 antibodies and fusion constructs and conjugates thereof |
| PE20212185A1 (es) | 2019-02-18 | 2021-11-11 | Lilly Co Eli | Formulacion de anticuerpos terapeuticos |
| PE20240329A1 (es) | 2019-06-05 | 2024-02-27 | Regeneron Pharma | Dispositivos y metodos para administracion de dosis de precision |
| CA3157509A1 (en) | 2019-10-10 | 2021-04-15 | Kodiak Sciences Inc. | Methods of treating an eye disorder |
| JP7713950B2 (ja) * | 2020-03-04 | 2025-07-28 | 上海復宏漢霖生物技術股▲フン▼有限公司 | ベバシズマブを含む薬物製剤 |
| CN113546172A (zh) * | 2020-04-24 | 2021-10-26 | 山东大学齐鲁医院 | Vegf抑制剂在制备治疗缺氧相关疾病药物中的应用 |
| US20210403568A1 (en) * | 2020-06-29 | 2021-12-30 | Cai Gu Huang | Biopharmaceutical formulation of anti-pd-1, anti-pd-l1, and anti-vegfr therapeutic monoclonal antibodies and method for treating nsclc by inhalation |
| US12649031B2 (en) | 2021-09-08 | 2026-06-09 | Regeneron Pharmaceuticals, Inc. | Methods for delivering agents with pre-filled syringes to minimize intraocular inflammation |
| USD1120314S1 (en) | 2022-11-30 | 2026-03-24 | Regeneron Pharmaceuticals, Inc. | Dose delivery device |
Family Cites Families (6)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US11078262B2 (en) * | 2007-04-30 | 2021-08-03 | Allergan, Inc. | High viscosity macromolecular compositions for treating ocular conditions |
| US8821870B2 (en) * | 2008-07-18 | 2014-09-02 | Allergan, Inc. | Method for treating atrophic age related macular degeneration |
| WO2012019136A2 (en) * | 2010-08-05 | 2012-02-09 | Forsight Vision 4, Inc. | Injector apparatus and method for drug delivery |
| WO2015200905A2 (en) * | 2014-06-28 | 2015-12-30 | Oligasis, Llc | Dual pdgf/vegf antagonists |
| CA3010329A1 (en) * | 2015-12-29 | 2017-07-06 | Oncobiologics, Inc. | Buffered formulations of bevacizumab |
| CN106924184B (zh) * | 2017-03-29 | 2020-07-17 | 烟台大学 | 一种眼部玻璃体注射用多囊脂质体及其制备方法 |
-
2019
- 2019-04-17 AU AU2019256289A patent/AU2019256289A1/en not_active Abandoned
- 2019-04-17 CN CN201980040536.7A patent/CN112543645A/zh active Pending
- 2019-04-17 WO PCT/US2019/027790 patent/WO2019204380A1/en not_active Ceased
- 2019-04-17 BR BR112020021255-5A patent/BR112020021255A2/pt not_active IP Right Cessation
- 2019-04-17 US US17/048,107 patent/US20210230261A1/en not_active Abandoned
- 2019-04-17 JP JP2020557256A patent/JP2021522180A/ja active Pending
- 2019-04-17 MX MX2020010968A patent/MX2020010968A/es unknown
- 2019-04-17 SG SG11202010178XA patent/SG11202010178XA/en unknown
- 2019-04-17 KR KR1020207033144A patent/KR20210011923A/ko not_active Abandoned
- 2019-04-17 EP EP19722351.4A patent/EP3781199A1/en not_active Withdrawn
- 2019-04-17 CA CA3097123A patent/CA3097123A1/en active Pending
-
2020
- 2020-10-14 IL IL278041A patent/IL278041A/en unknown
Also Published As
| Publication number | Publication date |
|---|---|
| AU2019256289A1 (en) | 2020-11-12 |
| BR112020021255A2 (pt) | 2021-02-02 |
| CN112543645A (zh) | 2021-03-23 |
| KR20210011923A (ko) | 2021-02-02 |
| MX2020010968A (es) | 2021-01-08 |
| SG11202010178XA (en) | 2020-11-27 |
| US20210230261A1 (en) | 2021-07-29 |
| CA3097123A1 (en) | 2019-10-24 |
| WO2019204380A1 (en) | 2019-10-24 |
| EP3781199A1 (en) | 2021-02-24 |
| JP2021522180A (ja) | 2021-08-30 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| SG11202010178XA (en) | Buffered formulations of bevacizumab for use of treating diseases | |
| ZA202004025B (en) | Novel compounds and pharmaceutical compositions thereof for the treatment of diseases | |
| IL276383A (en) | Treatment of ophthalmological diseases | |
| ZA202006610B (en) | Compositions for the treatment of skin conditions | |
| IL279397A (en) | New compounds and their pharmaceutical preparations for the treatment of diseases | |
| IL286340A (en) | Topical formulations for treatment of peripheral neuropathies | |
| IL280163A (en) | Mitochondrial augmentation therapy for primary mitochondrial diseases | |
| IL275754A (en) | Compounds, compositions, and methods for treating diseases involving infected acidic or hypoxic tissues | |
| ZA202007055B (en) | Compositions for the treatment of skin conditions | |
| ZA202006264B (en) | Stable formulations of therapeutic antibody | |
| ZA201906213B (en) | Compounds and methods for the treatment of parasitic diseases | |
| ZA202006234B (en) | Compositions and methods for the treatment of neurological diseases | |
| EP3744347A4 (en) | COMPOSITION FOR USE IN THE TREATMENT OF SKIN DISEASES | |
| IL282643A (en) | Soft combinations for the treatment of hematological diseases | |
| ZA202101587B (en) | Protein for treatment of inflammatory diseases | |
| GB201805100D0 (en) | Treatment of sarcopenic diseases | |
| GB201820018D0 (en) | Therapeutic hydrogel compositions | |
| CA3266235A1 (en) | COMPOSITIONS AND METHODS FOR THE TREATMENT OF SKIN DISEASES | |
| HUE069820T2 (hu) | Nalfurafin alkalmazása demielinizációs betegségek kezelésére | |
| IL280952A (en) | Methods and drug compounds for the treatment of ophthalmic diseases | |
| SG11202010034WA (en) | TREATMENT OF SKIN DISEASES OR DISORDERS BY DELIVERY OF ANTI-OSMRß ANTIBODY | |
| KR20180085033A (ko) | 피부 질환 치료용 약학적 제형 및 이의 제조 방법 | |
| KR102324922B9 (ko) | 오스테오칼신을 포함하는 염증성 질환의 예방 또는 치료용 약학 조성물 | |
| HK40044004A (en) | Buffered formulations of bevacizumab for use of treating diseases | |
| GB201909438D0 (en) | Treatment of diseases |